Incompatible receptors between the primary and secondary lesions of breast cancer have been reported, with frequencies of alterations in ER, PR, and HER2 being approximately 16.4%–32.4%, 30.9%–37.78%, and 10.2%–14.5%, respectively (7–10). This evidence concerns the gene ERBB2 and breast cancer.